SBSarah E. Burstein

Sarah E. Burstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah E. Burstein has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Skin Cancer in the Rural South: Strengthening Dermatologic Training for Frontline Primary Care

    by Sarah E Burstein, Howard I Maibach

    Skin cancer remains a major public health challenge in the rural Southeastern United States (US), where elevated disease burden coincides with limited access to dermatologic care. Rural populations face increased risk due to occupational exposure to ultraviolet light, poverty, lower rates of routine skin screening, and transportation barriers, yet many nonmetropolitan counties have no practicing dermatologists. Consequently, primary care physicians (PCPs) often serve as the first, and sometimes only, clinicians evaluating suspicious skin lesions. Despite this responsibility, dermatology remains underrepresented in undergraduate medical education and primary care training. Because dermatologic diagnosis relies heavily on pattern recognition, morphologic assessment, and familiarity with presentations across diverse skin tones, insufficient training may contribute to delayed recognition of premalignant and malignant lesions, particularly among medically underserved populations. This editorial argues that strengthening dermatologic education within general medical training is a pragmatic and immediately actionable strategy to address workforce maldistribution and reduce rural skin cancer disparities. This is not a proposal for PCPs to replace dermatologists, but rather a call to equip frontline clinicians with the foundational skills needed to recognize, triage, and appropriately manage high-risk dermatologic presentations.

  • The Effect of Sequential Topical Application of Dermatologic Medications on Absorption: Clinical Considerations

    by Sarah E. Burstein, Howard I. Maibach

    Background: Sequential application of topical dermatologic medications – defined as applying two or more agents to the same anatomical site within a short interval – is common in dermatologic therapy. Despite widespread clinical use, the pharmacologic consequences of application order, timing, and vehicle interactions on percutaneous absorption remain incompletely characterized. Summary: This review synthesizes clinical, in vivo human volunteer, and mechanistic in vitro and ex vivo evidence evaluating the impact of sequential topical application on cutaneous drug absorption and bioavailability. A qualitative literature search identified twelve eligible studies, including randomized controlled trials, in vivo human studies, and experimental diffusion and visualization models. Across heterogeneous study designs, sequential application was not pharmacologically neutral. Alterations in percutaneous absorption were driven by changes in stratum corneum barrier properties and vehicle or excipient interactions rather than formulation class alone. Sequencing effects were most pronounced when the first-applied product induced keratolysis, hydration or occlusion, or lipid film formation, or when vehicle redissolution and redistribution altered the effective treated surface area. In barrier-compromised conditions, such as atopic dermatitis, changes in application order were less likely to translate into measurable clinical effects. Fixed-combination formulations generally demonstrated more consistent and predictable cutaneous delivery than free sequential regimens. Key Messages: Sequential topical application can significantly influence percutaneous absorption through barrier modification and vehicle interactions. Pharmacokinetic effects are context-dependent and cannot be inferred solely from formulation type. Mechanism-informed sequencing and judicious selection of compatible vehicles may improve predictability of topical drug delivery, highlighting the need for standardized, pharmacologically focused studies to guide application order and timing.


  • Open Access

    Actinic keratosis metrics

    by Sarah E. Burstein, Howard Maibach

    Actinic keratosis (AK) is a common precancerous skin condition predominantly affecting older males with fair skin and significant UV exposure. The clinical significance of AK is related to its potential for malignant transformation and progression to squamous cell carcinoma (SCC). Accurate diagnosis of AK is essential for adequate treatment, evaluation of therapeutic efficacy, and mitigating the risk of developing SCC. However, clinician variability due to the subjective nature of current diagnostic tools presents significant challenges to achieving consistent and reliable AK diagnoses. Thus, there is no universally accepted standard for measuring AK.This review evaluates current methods for evaluating and diagnosing AK, focusing on clinician variability through inter- and intraobserver agreement. Eight peer-reviewed studies investigating the reliability of various approaches for AK evaluation show substantial variability in interobserver or intraobserver agreement, with most methods demonstrating only slight to moderate reliability. Some suggest that consensus discussions and simplified rating scales can modestly improve diagnostic reliability. However, remaining variability and the lack of a universally accepted standard for measuring AK underscore the need for more robust and standardized diagnostic and evaluation methods.The review emphasizes the need for improved diagnostic tools and standardized methods to enhance the accuracy and reliability of AK assessments. It also proposes applying a novel examination approach using 1,3-dihydroxyacetone (DHA) staining which may improve the visualization and identification of AK lesions. Advancements in these areas have significant potential, promising better clinical practices and patient outcomes in AK management.